Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies

@article{VillarPiqu2016StructureFA,
  title={Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies},
  author={Anna Villar-Piqu{\'e} and Tom{\'a}s Lopes da Fonseca and Tiago Fleming Outeiro},
  journal={Journal of Neurochemistry},
  year={2016},
  volume={139}
}
Parkinson's disease belongs to a group of currently incurable neurodegenerative disorders characterized by the misfolding and accumulation of alpha‐synuclein aggregates that are commonly known as synucleinopathies. Clinically, synucleinopathies are heterogeneous, reflecting the somewhat selective neuronal vulnerability characteristic of each disease. The precise molecular underpinnings of synucleinopathies remain unclear, but the process of aggregation of alpha‐synuclein appears as a central… 
Cellular models of alpha‐synuclein toxicity and aggregation
Misfolding and aggregation of alpha‐synuclein (α‐synuclein) with concomitant cytotoxicity is a hallmark of Lewy body related disorders such as Parkinson’s disease, dementia with Lewy bodies, and
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
TLDR
The role of α‐synuclein and β‐syn nuclein as potential biomarkers to improve the diagnostic characterization of synucleinopathies are discussed, thus highlighting their potential application in clinical trials for disease‐modifying therapies.
Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
TLDR
It appears that this protein may be a target for the development of neuroprotective drugs against PD, and many such potential drugs which prevent the expression, accumulation and aggregation of α-synuclein or its interactions with mitochondria or ER are discussed.
The emerging role of α-synuclein truncation in aggregation and disease
TLDR
Cumulatively, it is evident that truncation of αsyn, particularly carboxyl truncation that can be augmented by dysfunctional proteostasis, dramatically potentiates the propensity ofαsyn to pathologically misfold into uniquely toxic fibrils with modulated prion-like seeding activity.
Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease.
TLDR
Cumulative evidence implicates that abnormal processing of α-syn will be predicted to lead to pathological changes in PD, and suggests future directions for understanding the toxicity ofα-syn to neurons, which may ultimately encourage the design of disease-modifying therapeutic strategies for PD.
Release and uptake of pathologic alpha-synuclein
TLDR
The current state of knowledge about release and uptake of α-syn is reviewed and the key questions that remain unanswered are discussed.
Neuroinflammation and Alpha-Synuclein Oligomer Toxicity in the Pathogenesis of Lewy Body Dementia and Parkinson's Disease
TLDR
By identifying neuroinflammation as an α-synO-mediator and as a factor influencing the initiation/progressions of PD, this work highlights it as a valuable research topic to identify potential targets for developing new therapeutic strategies.
The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson’s disease
TLDR
This model provides insights into the function of α-synuclein and tau in Parkinson's disease pathogenesis and raises the possibility that this role that may also be conserved in Alzheimer’s disease is conserved.
Cathepsin Oxidation Alters Alpha-Synuclein Processing
TLDR
This paper proposes mitochondria-derived increased intralysosomal oxidative stress shifts cathepsin cleavage patterns to favor truncated forms of α-syn that increase its propensity to aggregate, and helps seed a grand unifying theory that bridges leading proposed mechanisms for Parkinson's disease pathogenesis.
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system
TLDR
Recent data demonstrating that manipulation of the glymphatic system may have the potential to alleviate and reduce pathogenic accumulation of propagation-prone intracellular cytotoxic proteins are discussed.
...
...

References

SHOWING 1-10 OF 253 REFERENCES
Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
TLDR
This review presents the available evidence on the properties of α-synuclein oligomers and the potential molecular mechanisms of their cellular disruption, and examines the relationship between α- synuclein toxic oligomer and amyloid fibrils, in the light of recent studies that paint a more complex picture ofα- Synuclein toxicity.
Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
TLDR
Detailed understanding of the biology/pathobiology of ASYN may enable the development of novel avenues for diagnosis and/or therapeutic intervention in synucleinopathies.
Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases
  • R. Melki
  • Biology
    Journal of Parkinson's disease
  • 2015
TLDR
Strategies targeting the formation and propagation of structurally distinct alpha-synuclein assemblies associated to different synucleinopathies are presented and their therapeutic and diagnostic potential is discussed.
Definition of a Molecular Pathway Mediating α-Synuclein Neurotoxicity
TLDR
A folding pathway for α-synuclein is delineated that ranges from a physiological multimeric, α-helical, and membrane-bound species that acts as a SNARE-complex chaperone over a monomeric, natively unfolded form to an amyloid-like aggregate that is neurotoxic in vivo.
Systematic Mutagenesis of α-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities
TLDR
The data show that the physiological function ofα-synuclein, although protective of neurodegeneration in some contexts, is fundamentally distinct from its neuropathological effects, thereby dissociating the two activities of α- synuclein.
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
TLDR
It is proposed that destabilization of the helically folded tetramer precedes α-synuclein misfolding and aggregation in Parkinson’s disease and other human synucleinopathies, and that small molecules that stabilize the physiological tetramer could reduce α- Synuclein pathogenicity.
The Function of α-Synuclein
α-Synuclein is phosphorylated in synucleinopathy lesions
TLDR
It is shown by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of α-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions and promoted fibril formation in vitro.
alpha-Synuclein is phosphorylated in synucleinopathy lesions.
TLDR
It is shown by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions and promoted fibril formation in vitro.
alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
TLDR
It is suggested that differences in aggregation kinetics of alpha-synucleins cannot be explained by differences in solubility but are due to different nucleation rates, and alpha- Synuclein nucleation may be the rate-limiting step for the formation of Lewy body alpha- synuclein fibrils in Parkinson's disease.
...
...